Supported by

Tricuspid / Pulmonary valve

Latest tricuspid content in interventional cardiology - research, practice, and education

Endovascular treatments for complications of the tricuspid or pulmonary valve, such as the treatment for tricuspid regurgitation (TR), are at an early stage of clinical development with many novel devices being introduced each year. This topic explores the different parameters of this emerging field with information on the latest research, emerging tools, devices and techniques, vascular access; the role of adjunctive pharmacotherapy; imaging techniques such as echocardiography as well as understanding bleeding risks or patient selection. Find out more…

Filtered By
Tricuspid / Pulmonary valve

492 results

How are the new ESC/EACTS valvular guidelines going to impact my tricuspid programme?

17 Nov 2025 – From PCR London Valves 2025

While the PCR London Valves 2025 Course is underway, Francesco Maisano and Fabien Praz discuss how the latest ESC/EACTS valvular guidelines affect clinical practice. What’s changing in surgery? How do repair and replacement strategies differ under the new recommendations, and what’s the impact on transcatheter interventions?...

How are the 2025 ESC/EACTS valvular guidelines going to impact my tricuspid programme?

Tricuspid valve: PCR London Valves 2025 highlights

18 Nov 2025 – From PCR London Valves 2025

At PCR London Valves 2025, Course Directors Francesco Maisano and Nicolo Piazza highlight with Chris Allen the rapid evolution of tricuspid interventions. They emphasise advances in imaging and simulation, with dedicated labs offering practical multimodality training and hands-on experience. LIVE cases showcased both repair and replacement...

Tricuspid valve: PCR London Valves 2025 highlights

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system

16 Nov 2025 – From PCR London Valves 2025

Rebecca Hahn, Varius Dannenberg and Matti Adam discuss the updated ESC/EACTS guidelines for tricuspid regurgitation, which upgrade transcatheter tricuspid interventions to a IIa recommendation. Evidence from the TRILUMINATE and TRISCEND II trials shows improved quality of life and reduced heart failure hospitalisations, especially in patients with...

From pivotal trial to real-world impact: shaping TR treatment today with the EVOQUE system #PCRLV

Patient-tailored TAVI in bicuspid and tricuspid aortic stenosis

16 Nov 2025 – From PCR London Valves 2025

This session focuses on patient-tailored TAVI strategies for bicuspid and tricuspid aortic stenosis. It reviews recent comparative studies of TAVI devices, discusses the development of individualized TAVI programs for tricuspid aortic stenosis patients, and provides guidance on selecting optimal devices for those with bicuspid aortic valve...

Patient-tailored TAVI in bicuspid and tricuspid aortic stenosis

Hotline - Mitral and tricuspid valvular interventions

16 Nov 2025 – From PCR London Valves 2025

This session delves into innovative mitral and tricuspid valvular interventions, highlighting outcomes with the PASCAL precision system and advances in combined MitraClip and TriClip repairs. It discusses predictors of heart failure hospitalization post-transcatheter tricuspid valve repair (TTVR), coronary CT-based pacemaker implantation prediction, and novel devices aimed...

Complex mitral and tricuspid TEER

16 Nov 2025 – From PCR London Valves 2025

This session highlights complex cases in mitral and tricuspid transcatheter edge-to-edge repair (TEER), addressing challenges such as septal obstacles in patients with old atrial septal occluders, management of residual atrial septal defects post-mitral valve-in-ring replacement, and innovative multidisciplinary approaches. It also covers hybrid transapical mitral valve-in-valve...

Cutting-edge research in transcatheter tricuspid valve therapies

16 Nov 2025 – From PCR London Valves 2025

This session highlights cutting-edge research on tricuspid valve interventions, including the impact of inflow gradients on outcomes, global registry data on bicaval valve therapy, patient selection algorithms, and prognostic score validations for severe tricuspid regurgitation.

Cutting-edge research in transcatheter tricuspid valve therapies

New tricuspid valve devices

16 Nov 2025 – From PCR London Valves 2025

Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.

Tricuspid valve interventions in complex scenarios

16 Nov 2025 – From PCR London Valves 2025

This session explores tricuspid valve interventions in complex clinical scenarios, emphasizing emerging techniques such as electrosurgical laceration to enable TTVR, emergency TEER for papillary muscle rupture, and expanded options for difficult valve disease. It also addresses procedural challenges when conventional implantation maneuvers fail, transcatheter alternatives for...

Transcatheter tricuspid valve replacement

16 Nov 2025 – From PCR London Valves 2025

This session reviews contemporary advances in transcatheter tricuspid valve replacement (TTVR). It highlights long-term follow-up data from tricuspid valve-in-valve cases, introduces the novel Vdyne valve device for tricuspid regurgitation, and discusses timing considerations for interventions following surgical aortic valve replacement. Additionally, it evaluates the role of...